Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Gossamer Bio is a clinical-stage biopharmaceutical company focused on developing immunology therapeutics, with lead asset seralutinib targeting pulmonary arterial hypertension (PAH) in Phase 3 trials and GB002 for ulcerative colitis. The company operates with minimal revenue ($0.1M TTM), burning approximately $50M annually in operating cash flow, and relies on capital markets to fund clinical development through anticipated data readouts. Stock performance is driven entirely by clinical trial milestones, regulatory decisions, and financing events rather than commercial fundamentals.
Gossamer operates a classic clinical-stage biotech model with no meaningful commercial revenue. The company monetizes R&D through three potential pathways: (1) successful clinical development leading to FDA approval and commercial launch of proprietary products, (2) out-licensing or partnership deals that provide upfront payments and milestone-based revenue, or (3) acquisition by larger pharmaceutical companies seeking pipeline assets. With 100% gross margins on minimal revenue and -52% operating margins, the business model is entirely dependent on advancing seralutinib (PAH indication) and GB002 (inflammatory bowel disease) through clinical trials. Current cash runway estimated at 12-18 months based on $50M annual burn rate and 3.28x current ratio suggests adequate near-term liquidity but likely need for additional financing before commercialization.
Phase 3 seralutinib trial data readouts for pulmonary arterial hypertension (primary endpoint: change in pulmonary vascular resistance)
FDA regulatory interactions including breakthrough therapy designation decisions, advisory committee meetings, and approval timelines
Capital raising announcements (equity offerings, ATM programs, debt facilities) which signal runway extension but create dilution concerns
Partnership or licensing deals with larger pharmaceutical companies that validate pipeline assets and provide non-dilutive funding
Competitive clinical data from rival PAH therapies (Merck's sotatercept, United Therapeutics' products) that reset market expectations
Binary clinical trial risk - Phase 3 seralutinib failure would eliminate primary value driver and likely trigger significant equity decline (70-90% downside typical for failed lead assets). PAH is competitive market with established therapies.
Capital markets dependency - company requires additional financing before potential commercialization in 2027-2028. Biotech financing windows can close rapidly during market stress, forcing dilutive raises or program cuts.
Regulatory approval uncertainty - FDA standards for PAH therapies require demonstrable improvement in hemodynamic parameters and functional capacity. Advisory committee rejections or clinical holds can extend timelines 12-24+ months.
Merck's sotatercept (approved March 2024 for PAH) has established first-mover advantage in novel mechanism category, potentially limiting seralutinib's market opportunity and pricing power
United Therapeutics dominates PAH market with multiple approved products (Tyvaso, Remodulin, Orenitram) and deep KOL relationships, creating high barriers for new entrants to gain formulary access and physician adoption
Acceleron/Merck, Janssen, and other large pharma have well-funded PAH programs that could produce superior efficacy data or reach market faster
Negative equity position (ROE of 593.8% with negative book value) indicates accumulated deficits exceed assets, typical for pre-revenue biotechs but signals extended cash burn history
Estimated 12-18 month cash runway based on current burn rate requires near-term financing, likely in 2026-2027, creating dilution risk and dependence on favorable market conditions
No debt cushion or credit facilities disclosed - company appears entirely equity-financed, limiting financial flexibility during market downturns
low - Clinical trial timelines and FDA regulatory processes are largely insulated from GDP fluctuations. However, severe recessions can impact: (1) ability to raise capital as risk appetite declines and biotech IPO/follow-on markets freeze, (2) partnership deal flow as pharma companies conserve cash, and (3) patient enrollment if economic stress affects healthcare access. PAH is a serious orphan disease with limited treatment options, creating relatively inelastic demand regardless of economic conditions.
Rising interest rates negatively impact Gossamer through two primary channels: (1) Valuation compression - clinical-stage biotechs are valued on discounted future cash flows from potential products 3-5+ years out, making them highly sensitive to discount rate changes. Higher rates reduce NPV of pipeline assets. (2) Capital access - higher risk-free rates make speculative biotech investments less attractive relative to bonds, tightening financing conditions and increasing dilution costs. The company's -$50M annual cash burn makes it dependent on favorable capital markets. With current 3.28x current ratio and minimal debt, direct interest expense impact is negligible.
Minimal direct credit exposure given negligible debt levels (negative debt/equity ratio suggests more cash than debt). However, indirect credit exposure exists through capital markets access - widening high-yield spreads and tightening credit conditions correlate with reduced biotech financing availability, forcing companies to raise capital at less favorable terms or delay programs. Gossamer's survival depends on maintaining access to equity capital markets rather than traditional credit facilities.
growth - Attracts speculative biotech investors seeking asymmetric risk/reward from binary clinical catalysts. Typical holders include specialized healthcare hedge funds, biotech-focused mutual funds, and retail investors with high risk tolerance. Not suitable for value or income investors given negative earnings, no dividends, and uncertain commercialization timeline. Recent 57% one-year return despite -29% three-month decline reflects high volatility around clinical milestones and financing events.
high - Clinical-stage biotechs exhibit extreme volatility around binary events (trial data, FDA decisions). Stock can move 30-70% in single session on trial results. Small market cap ($500M) and low float amplify price swings. Beta likely 1.5-2.0x relative to broader market, with idiosyncratic risk dominating systematic risk. Three-month -29% decline followed by six-month +9% return demonstrates characteristic whipsaw pattern.
